EU opens first probe into abusive drug patent filings

The European Commission is investigating whether Teva Pharmaceuticals unlawfully delayed the entry of generic drugs to treat multiple sclerosis through patent litigation and a disparaging communications campaign that discredited its competitors.


Get unlimited access to all Global Competition Review content